



*Crédit: CRCHU de Québec*

## **A NEW DIRECTION**

After completing the change of management process according to the rules of the Fonds de recherche du Québec – Santé, we are pleased to announce that Dr. Jean-Yves Masson PhD, FCAHS has been appointed incoming director at RRCancer.

### **Get to know Jean-Yves Masson better**

Dr. Masson is a regular researcher at the CHU de Québec-Université Laval Research Center, Oncology axis and is a full professor in the Department of Molecular Biology, Medical Biochemistry and Pathology of the Faculty of Medicine at Laval University. He holds a Canada Research Chair in DNA Repair and Therapeutic Approaches to Cancer. Dr. Masson is also a world leader in genomic instability.

He was also involved at his institution where he was the representative for the fundamental sector

in the planning and coordination committee of the center of

cancer research/Oncology axis in 2011 and member of the

director of the Oncology axis in 2012. From 2013-2017, he directed the department of

Molecular Biology, Medical Biochemistry and Pathology, which brings together nearly 40 fundamentalist teachers or clinicians.

### **A planned year of transition**

Dr. Masson took office a few days ago and will co-direct the RRCancer with Dr. Mes-Masson for the next six months, thus allowing the transfer of knowledge for the continuity of the RRCancer while promoting an optimal transition. In addition, meetings with the directors of the RRCancer axes will take place with the objective of updating the strategic plan for the coming years. As of April 2023, Dr. Masson will perform the full functions of the management of RRCancer.

### **The Best of Success**

Jean-Yves, we wish you the best of success in this new adventure. The regular members of the RRCancer are confident that your expertise and your abilities will be assets to maintain the achievements of the RRCancer and propel it towards new horizons under the umbrella of the Oncopole.